114,900 Shares in Kyverna Therapeutics, Inc. $KYTX Acquired by 683 Capital Management LLC

683 Capital Management LLC purchased a new position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 114,900 shares of the company’s stock, valued at approximately $1,080,000.

A number of other large investors also recently added to or reduced their stakes in KYTX. Phoenix Wealth Advisors increased its stake in Kyverna Therapeutics by 17.1% in the 4th quarter. Phoenix Wealth Advisors now owns 12,300 shares of the company’s stock worth $116,000 after acquiring an additional 1,800 shares during the last quarter. Public Employees Retirement System of Ohio bought a new stake in Kyverna Therapeutics in the 3rd quarter worth approximately $28,000. Federated Hermes Inc. increased its stake in Kyverna Therapeutics by 36.6% in the 4th quarter. Federated Hermes Inc. now owns 20,705 shares of the company’s stock worth $195,000 after acquiring an additional 5,547 shares during the last quarter. Rhumbline Advisers increased its stake in Kyverna Therapeutics by 22.0% in the 1st quarter. Rhumbline Advisers now owns 31,614 shares of the company’s stock worth $61,000 after acquiring an additional 5,694 shares during the last quarter. Finally, Bank of America Corp DE increased its stake in Kyverna Therapeutics by 41.6% in the 4th quarter. Bank of America Corp DE now owns 21,788 shares of the company’s stock worth $81,000 after acquiring an additional 6,400 shares during the last quarter. 18.08% of the stock is owned by hedge funds and other institutional investors.

Kyverna Therapeutics Price Performance

Kyverna Therapeutics stock opened at $8.04 on Thursday. The stock has a market cap of $488.75 million, a price-to-earnings ratio of -2.45 and a beta of 1.95. The company has a debt-to-equity ratio of 0.13, a current ratio of 8.15 and a quick ratio of 8.15. Kyverna Therapeutics, Inc. has a 1 year low of $2.52 and a 1 year high of $13.67. The firm has a 50-day moving average of $8.94 and a two-hundred day moving average of $8.56.

Kyverna Therapeutics (NASDAQ:KYTX) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.09. On average, research analysts forecast that Kyverna Therapeutics, Inc. will post -2.78 earnings per share for the current year.

Analyst Ratings Changes

KYTX has been the topic of a number of research reports. Wall Street Zen downgraded Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Friday, March 27th. HC Wainwright reissued a “buy” rating and set a $25.00 target price on shares of Kyverna Therapeutics in a research report on Wednesday, June 3rd. Finally, JPMorgan Chase & Co. cut their target price on Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 13th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Kyverna Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $30.00.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.